Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 4/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.35 |
| ▸ | CIT | O14578 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053796 | 0.92 | CCR3 (0.41) | JAK2BRAFCYP2C9CYP3A4MEN1 | |
| SCHEMBL3705534 | 0.92 | GOT1 (0.42) | GOT1MAP3K7CNR1P2RY1AURKA | |
| SCHEMBL15052837 | 0.90 | AURKA (0.42) | MAP3K7AURKAAURKBLYNIGF1R | |
| SCHEMBL15053103 | 0.90 | MAP3K7 (0.39) | GOT1MAP3K7AURKAAURKBLYN | |
| SCHEMBL15053541 | 0.90 | BTK (0.40) | GOT1MAP3K7CNR1AURKAAURKB | |
| SCHEMBL15053470 | 0.90 | BTK (0.40) | MAP3K7AURKAAURKBLYNIGF1R | |
| SCHEMBL15053942 | 0.90 | JAK2 (0.38) | JAK2BRAFCYP2C9CYP3A4CIT | |
| SCHEMBL15053064 | 0.90 | MAP3K7 (0.41) | MAP3K7AURKAAURKBLYNIGF1R | |
| SCHEMBL15054399 | 0.89 | P2RY1 (0.40) | GOT1CNR1P2RY1METBRAF | |
| SCHEMBL15052843 | 0.88 | BRAF (0.45) | GOT1MAP3K7P2RY1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | GOT1 1829/4885MAP3K7 48/4885CNR1 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.